Abstract:T cell immunoglobulin-3 (TIM-3) has been established as a negative regulatory molecule and plays a critical role in immune tolerance. TIM-3 is upregulated in exhausted CD8(+) T cells in both chronic infection and tumor. However, the nature of TIM-3(+)CD4(+) T cells in the tumor microenvironment is unclear. This study is to characterize TIM-3 expressing lymphocytes within human lung cancer tissues and establish clinical significance of TIM-3 expression in lung cancer progression.A total of 51 human lung cancer tissue specimens were obtained from pathologically confirmed and newly diagnosed non-small cell lung cancer (NSCLC) patients. Leukocytes from tumor tissues, distal normal lung tissues, and peripheral blood mononuclear cells (PBMC) were analyzed for TIM-3 surface expression by flow cytometry. TIM-3 expression on tumor-infiltrating lymphocytes (TILs) was correlated with clinicopathological parameters.TIM-3 is highly upregulated on both CD4(+) and CD8(+) TILs from human lung cancer tissues but negligibly expressed on T cells from patients' peripheral blood. Frequencies of IFN-γ(+) cells were reduced in TIM-3(+)CD8(+) TILs compared to TIM-3(-)CD8(+) TILs. However, the level of TIM-3 expression on CD8(+) TILs failed to associate with any clinical pathological parameter. Interestingly, we found that approximately 70% of TIM-3(+)CD4(+) TILs expressed FOXP3 and about 60% of FOXP3(+) TILs were TIM-3(+). Importantly, TIM-3 expression on CD4(+) T cells correlated with poor clinicopathological parameters of NSCLC such as nodal metastasis and advanced cancer stages. Our study reveals a new role of TIM-3 as an important immune regulator in the tumor microenvironment via its predominant expression in regulatory T cells.

Ectopic expression of Tim-3 induces tumor-specific antitumor immunity

Notice of Retraction Ectopic Expression of Tim-3 Induces Tumor-Specific Antitumor Immunity

TIM-3, a Promising Target for Cancer Immunotherapy

Tim-3 Expression Defines Regulatory T Cells in Human Tumors

Expression of Tim-3 drives phenotypic and functional changes in Treg cells in secondary lymphoid organs and the tumor microenvironment

A TIM-3 Oligonucleotide Aptamer Enhances T Cell Functions and Potentiates Tumor Immunity in Mice

TIM-3 As a Target for Cancer Immunotherapy and Mechanisms of Action.

Spatial distribution and functional analysis define the action pathway of Tim-3/Tim-3 ligands in tumor development

Tim-3 promotes cell aggressiveness and paclitaxel resistance through NF-κB/STAT3 signalling pathway in breast cancer cells

PUB044 TIM-3 Protein Expression in Non-Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes

Tim-3 promotes cell aggressiveness and paclitaxel resistance through NF-B/STAT3 signalling pathway in breast cancer cells

The role of Tim-3 blockade in the tumor immune microenvironment beyond T cells

T Cell Immunoglobulin and Mucin-Domain Containing-3 in Non-Small Cell Lung Cancer

TIM-3 inhibitors: a promising strategy for tumor immunotherapy

Expression and clinical significance of Tim-3 on CD8 +T cell from peripheral blood of melanoma patients

TIM-3 Expression Characterizes Regulatory T Cells in Tumor Tissues and is Associated with Lung Cancer Progression

A novel antibody targeting TIM-3 resulting in receptor internalization for cancer immunotherapy

TIM-3 restrains anti-tumour immunity by regulating inflammasome activation

TIM-3 as a promising target for cancer immunotherapy in a wide range of tumors

Tim-3 promotes cell aggressiveness and paclitaxel resistance through the NF-κB /STAT3 signaling pathway in breast cancer

Tim-3 expression and its role in hepatocellular carcinoma